|
July
Thursday, Jul 02, 2009 Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion May Saturday, May 30, 2009 Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer Saturday, May 30, 2009 Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin as First-Line Maintenance Therapy Friday, May 29, 2009 Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer Tuesday, May 19, 2009 Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia Thursday, May 14, 2009 Genentech to Present Advances With Targeted Cancer Medicines at ASCO Tuesday, May 05, 2009 FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy April Tuesday, Apr 21, 2009 Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint Wednesday, Apr 08, 2009 Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market See the Archives 
 |
